NIM
AUTL

NEOS Investment Management’s Autolus Therapeutics AUTL Stock Holding History

NEOS Investment Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-115,823
Closed -$189K – 652
2025
Q3 		$189K Sell
115,823
-4,565
-4% -$8.92K ﹤0.01% 625
2025
Q2 		$274K Buy
120,388
+9,960
+9% +$16.5K ﹤0.01% 591
2025
Q1 		$171K Buy
+110,428
New +$224K ﹤0.01% 592

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

NEOS Investment Management's AUTL Position: Q4 2025 in Review

NEOS Investment Management sold out of Autolus Therapeutics (AUTL) in Q4 2025, closing a stake of 115,823 shares — an estimated $189K sold.

NEOS Investment Management first reported a position in AUTL in Q1 2025 and held it in 3 quarters. The position peaked at $274K in Q2 2025. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • NEOS Investment Management reported no remaining Autolus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • NEOS Investment Management sold 115,823 Autolus Therapeutics shares in Q4 2025, an estimated $189K.
  • NEOS Investment Management first reported a position in Autolus Therapeutics in Q1 2025 and held it in 3 quarters.
  • NEOS Investment Management's Autolus Therapeutics position peaked at $274K in Q2 2025.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on NEOS Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.